

<http://www.oblible.com>

424B2 1 d424b2.htm PRICING SUPPLEMENT BARC 13YR 5.00% WITH SURVIVOR'S OPTION BLACK
CALCULATION OF REGISTRATION FEE

<i>Title of Each Class of Securities Offered</i>	<i>Maximum Aggregate Offering Price</i>	<i>A</i>
Global Medium-Term Notes, Series A	\$2,118,000	

(1) Calculated in accordance with Rule 457(r) of the Securities Act of 1933.

<http://www.oblible.com>

Pricing Supplement dated April 23, 2010
(To Prospectus dated February 10, 2009 and
the Prospectus Supplement dated March 1, 2010)

<http://www.sec.gov/Archives/edgar/data/312070/000119312510094777/d424b2.htm>

Pricing Supplement BARC 13yr 5.00% with Survivor's Option Black



US\$2,118,000

5.00% FIXED RATE NOTES DUE APRIL 28, 2023

Principal Amount:	US\$2,118,000	Issuer:	Barclays Bank PLC (Rated AA-/Aa3) ⁽¹⁾
Issue Price:	100%	Series:	Global Medium-Term Notes, Series
Original Issue Date:	April 28, 2010	Principal Protection Percentage:	100%
Interest Rate Type:	Fixed Rate	Original Trade Date:	April 23, 2010
Maturity Date:	April 28, 2023	CUSIP:	06738JAZ7
		ISIN:	US06738JAZ75
Denominations:	Minimum denominations of US\$1,000 and integral multiples of US\$1,000 thereafter.	Business Day:	<input checked="" type="checkbox"/> New York <input checked="" type="checkbox"/> London <input type="checkbox"/> Euro <input type="checkbox"/> Other ()
Interest Rate:	5.00%		
Interest Payment Dates:	<input type="checkbox"/> Monthly, <input type="checkbox"/> Quarterly, <input checked="" type="checkbox"/> Semi-Annually, <input type="checkbox"/> Annually, payable in arrears on every 28 th of April and October, commencing on October 28, 2010 and ending on the Maturity Date.		
Survivor's Option:	Upon request by the authorized representative of the beneficial owner of the Notes, we will repay those Notes prior to the Maturity Date following the death of the beneficial owner of the Notes, provided such Notes were acquired by the deceased beneficial owner at least six months prior to the date of the request. The right to exercise this option will be subject to: • a permitted dollar amount of total exercises by all holders of these Notes in any calendar year; and • the permitted dollar amount of an individual exercise by a holder of these Notes in any calendar year. For additional details regarding the Survivor's Option, see "Description of Survivor's Option" below.		
Business Day Convention:	Following, Unadjusted	Day Count Convention:	30/360
Settlement:	DTC; Book-entry; Transferable.		
Listing:	The Notes will be not listed on any U.S. securities exchange or quotation system.		

	Price to Public	Agent's Commission ⁽¹⁾	Proceeds to Barclays Bank
Per Note	100%	1.40%	98.60%
Total	\$2,118,000	\$29,652	\$2,088,348

(1) Barclays Capital Inc. will receive commissions from the issuer equal to 1.40% of the principal amount of the notes, or \$14.00 per \$1,000 principal amount, and retain all or a portion of these commissions or use all or a portion of these commissions to pay selling concessions or fees to other dealers.

The Notes will not be listed on any U.S. securities exchange or quotation system. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined that this pricing supplement is truthful or complete. Any representation to the contrary is a criminal offense.

We may use this pricing supplement in the initial sale of Notes. In addition, Barclays Capital Inc. or another of our affiliates may use this pricing supplement in market resale transactions in any Notes after their initial sale. Unless we or our agent informs you otherwise in the confirmation of sale, this pricing supplement is being used in a market resale transaction.

Pricing Supplement BARC 13yr 5.00% with Survivor's Option Black



Pricing Supplement BARC 13yr 5.00% with Survivor's Option Black

The Notes constitute our direct, unconditional, unsecured and unsubordinated obligations and are not deposit liabilities of Barclays Bank PLC, the U.S. Federal Deposit Insurance Corporation or any other governmental agency of the United States, the United Kingdom or any other country.

Investing in the Notes involves a number of risks. See “Risk Factors” beginning on page S-5 of the prospectus supplement and “Selected Risk Factors” beginning on page S-10 of the prospectus supplement. You should consult your investment, legal, tax, accounting and other advisers and to invest in the Notes only after you and your advisers have considered the suitability of an investment in the Notes in light of your particular circumstances.

Barclays Bank PLC has filed a registration statement (including a prospectus) with the SEC for the offering to which this pricing supplement relates. You should read the prospectus dated February 10, 2009, the prospectus supplement dated March 1, 2010, and other documents Barclays Bank PLC has filed with the SEC for more complete information about Barclays Bank PLC and this offering. Buyers should rely upon this pricing supplement, the prospectus, the prospectus supplement, and any relevant free writing prospectus or pricing supplement for complete details. You may get these documents and other information filed by Barclays Bank PLC for free by visiting EDGAR on the SEC website at www.sec.gov, and you may also access the prospectus and prospectus supplement below:

- **Prospectus dated February 10, 2009:**
<http://www.sec.gov/Archives/edgar/data/312070/000119312509023285/dposasr.htm>
- **Prospectus Supplement dated March 1, 2010:**
<http://www.sec.gov/Archives/edgar/data/312070/000119312510043357/d424b3.htm>

Our Central Index Key, or CIK, on the SEC website is 1-10257.

Alternatively, Barclays Capital Inc. or any agent or dealer participating in this offering will arrange to send you this pricing supplement and any related free writing prospectus if you request it by calling your Barclays Capital Inc. sales representative, such as (212) 353-3430. A copy of the prospectus may be obtained from Barclays Capital Inc., 745 Seventh Avenue—Attn: US InvSol Support, New York, NY 10019.

You may revoke your offer to purchase the Notes at any time prior to the time at which we accept such offer by notifying the applicable agent or dealer of your revocation, or reject any offer to purchase the Notes prior to their issuance. In the event of any changes to the terms of the Notes, we will notify you of such changes in connection with your purchase. You may also choose to reject such changes in which case we may reject your offer to purchase the Notes.

As used in this term sheet, the “Company,” “we,” “us,” or “our” refers to Barclays Bank PLC.

Pricing Supplement BARC 13yr 5.00% with Survivor's Option Black

PROGRAM CREDIT RATING

The Notes are issued under the Global Medium-Term Notes Program, Series A (the “Program”). The Program is rated AA– by Standard & Poor’s. The Notes are expected to carry the same S&P rating as the Program rating. An AA– rating from S&P generally indicates that the issuer’s capacity to service the obligations arising from the Program is very strong. This rating does not take into account market risk or the performance-related risk (including, but not limited to, the risk of a rating downgrade or withdrawal of the rating) of the reference asset to which the Notes are linked). The Program is managed by Moody’s Services, Inc. (“Moody’s”); however, because we have not sought a rating from Moody’s for this specific issuance, the Notes will not be rated by Moody’s. The ratings in this paragraph are subject to downward revision, suspension or withdrawal at any time by the assigning rating organization and are not a recommendation to buy or sell securities.

SELECTED RISK FACTORS

An investment in the Notes involves significant risks. You should read the risks summarized below in connection with, and the risks described in more detail in the “Risk Factors” section beginning on page S-5 of the prospectus supplement. We urge you to consult your investment, legal, tax, accounting and other advisers and to invest in the Notes only after you and your advisers have carefully considered the risks in the Notes in light of your particular circumstances.

- **Issuer Credit Risk**—You will receive at least 100% of the principal amount of your Notes if you hold your Notes to the Maturity Date. However, payment of any interest or any amount at maturity is subject to our ability to pay our obligations on the Maturity Date. We are a subsidiary of Barclays Bank PLC, and our senior unsecured obligations, payment of any interest or any amount at maturity is subject to our ability to pay our obligations on the Maturity Date.
- **Certain Built-In Costs Are Likely to Adversely Affect the Value of the Notes Prior to Maturity**—Although you will not receive any interest on the Notes if you hold the Notes to maturity, the Original Issue Price of the Notes includes the agent’s commission and the cost of the Notes through one or more of our affiliates. As a result, assuming no change in market conditions or any other relevant factors, the Original Issue Price of the Notes may be less than the price at which Barclays Capital Inc. and other affiliates of Barclays Bank PLC will be willing to purchase Notes from you in secondary market transactions. The Original Issue Price, and any sale prior to the Maturity Date could result in a substantial loss to you.
- **Potential Conflicts**—We and our affiliates play a variety of roles in connection with the issuance of the Notes, including hedging and performing these duties, the economic interests of our affiliates of ours are potentially adverse to your interests as an investor. In addition, Barclays Wealth, the wealth management division of Barclays Capital Inc., may arrange for the sale of the Notes. Barclays Wealth will be acting as agent for Barclays Bank PLC and may receive compensation from Barclays Bank PLC in the form of fees. The role of Barclays Wealth as a provider of certain services to such customers and as agent for Barclays Bank PLC in connection with the issuance of the Notes may create a potential conflict of interest, which may be adverse to such clients. Barclays Wealth is not acting as an investment adviser to investors and is not representing you in any capacity with respect to any purchase of Notes by you. Barclays Wealth is acting solely as agent for Barclays Bank PLC. Considering whether to invest in the Notes through Barclays Wealth, we strongly urge you to seek independent financial and investment advice in connection with such investment.
- **Lack of Liquidity**—The Notes will not be listed on any securities exchange. Barclays Capital Inc. and other affiliates of Barclays Bank PLC may make a secondary market for the Notes but are not required to do so, and may discontinue any such secondary market making at any time. If there is no active secondary market, it may not provide enough liquidity to allow you to trade or sell the Notes easily. Because other dealers are not making a market for the Notes, the price at which you may be able to trade your Notes is likely to depend on the price, if any, at which Barclays Bank PLC are willing to buy the Notes. The Notes are not designed to be short-term trading instruments. Accordingly, you should hold your Notes to maturity.

Pricing Supplement BARC 13yr 5.00% with Survivor's Option Black

- **Many Economic and Market Factors Will Impact the Value of the Notes**—The value of the Notes will be affected by a number of factors that may either offset or magnify each other, including:
 - the time to maturity of the Notes;
 - interest and yield rates in the market generally;
 - a variety of economic, financial, political, regulatory or judicial events; and
 - our creditworthiness, including actual or anticipated downgrades in our credit ratings.

DESCRIPTION OF SURVIVOR'S OPTION

Upon request by the authorized representative of the beneficial owner of the Notes, Barclays Bank PLC will repay those Notes prior to the maturity of the Notes (the **“Survivor’s Option”**), provided such Notes were acquired by the deceased beneficial owner at least six months prior to the date of death. Upon the valid exercise of the Survivor’s Option and the proper tender of the Notes for repayment, Barclays Bank PLC will repay such Notes to 100% of the principal amount of the deceased beneficial owner’s beneficial interest in the Notes plus accrued and unpaid interest to the date of death. In this section, a beneficial owner of Notes is a person who has the right, immediately prior to such person’s death, to receive the proceeds from the Notes. The right to receive payment of the principal of the Notes.

To be valid, the Survivor’s Option must be exercised by or on behalf of the person who has authority to act on behalf of the deceased beneficial owner of the applicable jurisdiction (including, without limitation, the personal representative of or the executor of the estate of the deceased beneficial owner with the deceased beneficial owner).

The death of a person holding a beneficial ownership interest in the Notes: (1) with any person in a joint tenancy with right of survivorship; or (2) by the entirety, tenancy in common, as community property or in any other joint ownership arrangement, will be deemed the death of a beneficial owner. The entire principal amount of the Notes held in this manner will be subject to repayment by Barclays Bank PLC upon request. However, the death of a person holding a beneficial ownership interest in Notes as tenant in common with a person other than his or her spouse will be deemed the death of a beneficial owner of the person’s interest in the Notes, and only the deceased beneficial owner’s percentage interest in the principal amount of the Notes will be subject to repayment.

If the ownership interest in the Notes is held by a nominee for a beneficial owner or by a custodian under a Uniform Gifts to Minors Act or a trustee of a trust that is wholly revocable by the beneficial owner, or by a guardian or committee for a beneficial owner, the death of the beneficiary will constitute death of the beneficial owner for purposes of the Survivor’s Option, if the beneficial ownership interest can be established to the satisfaction of the applicable jurisdiction. In these cases, the death of the nominee, custodian, trustee, guardian or committee will not be deemed the death of the beneficial owner of the Notes for purposes of the Survivor’s Option.

Barclays Bank PLC has the discretionary right to limit the aggregate principal amount of the Notes as to which exercises of the Survivor’s Option may be made by authorized representatives of deceased beneficial owners in any calendar year, to an amount equal to 2.0% of the aggregate amount of the Notes outstanding as of the most recent calendar year.

Barclays Bank PLC also has the discretionary right to limit to \$250,000 the aggregate principal amount of Notes as to which exercises of the Survivor’s Option may be made by Barclays Bank PLC from the authorized representative for any individual deceased beneficial owner of such notes in any calendar year. In addition, Barclays Bank PLC will not permit the exercise of the Survivor’s Option (a) for a principal amount less than \$1,000, or (b) if such exercise will result in a beneficial owner of the Notes with a principal amount of less than \$1,000 outstanding.

An otherwise valid election to exercise the Survivor’s Option may not be withdrawn. Elections to exercise the Survivor’s Option will be accepted only if accepted and approved by Barclays Bank PLC, except for any election the acceptance of which would contravene any of the limitations described above.

Pricing Supplement BARC 13yr 5.00% with Survivor's Option Black

through the exercise of the Survivor's Option will be repaid on the first Interest Payment Date that occurs 60 or more calendar days after the Note is tendered to Barclays Bank PLC. Each tendered Note that is not accepted in any calendar year due to the application of any of the limitations described in the Supplement will be deemed to be tendered in the following calendar year in the order in which all such Notes were originally tendered. If a Note tendered through the exercise of the Survivor's Option is not accepted by Barclays Bank PLC, the trustee, upon receipt of a valid written instruction from Barclays Bank PLC or its agent, will be repaid to the Noteholder that states the reason that Note has not been accepted for repayment.

PS-2

Pricing Supplement BARC 13yr 5.00% with Survivor's Option Black

Because the Notes will be issued in book-entry form (except in very limited circumstances), DTC or its nominee will be treated as the holder that receives notices from Barclays Bank PLC (or the trustee) and, on behalf of the deceased beneficial owner's authorized representative, will exercise the Survivor's Option for such Notes. To obtain repayment of the Notes pursuant to exercise of the Survivor's Option, the deceased beneficial owner must provide the following items to the broker or other entity through which the beneficial interest in the Notes is held by the deceased beneficial owner:

- appropriate evidence satisfactory to Barclays Bank PLC that:
 - (1) the deceased was the beneficial owner of the Notes at the time of death and his or her interest in the Notes was acquired at least six months prior to the request for repayment,
 - (2) the death of the beneficial owner has occurred and the date of death, and
 - (3) the representative has authority to act on behalf of the deceased beneficial owner;
- if the beneficial interest in the Notes is held by a nominee or trustee of, custodian for, or other person in a similar capacity to, the deceased beneficial owner, evidence satisfactory to Barclays Bank PLC from the nominee, trustee, custodian or similar person attesting to the deceased beneficial owner's ownership of the Notes;
- a written request for repayment signed by the authorized representative of the deceased beneficial owner with the signature guaranteed in the Security Transfer Agents Medallion Program, the New York Stock Exchange Medallion Signature Program or the Stock Exchange Automated Transfer System (generally a member of a registered national securities exchange, a member of the Financial Industry Regulatory Authority, or having an office in the United States);
- tax waivers and any other instruments or documents that Barclays Bank PLC reasonably requires in order to establish the validity of the Notes and the claimant's entitlement to payment; and
- any additional information Barclays Bank PLC requires to evidence satisfaction of any conditions to the exercise of the Survivor's Option, the ownership or authority to make the election and to cause the repayment of the Notes.

In turn, the broker or other entity will deliver each of these items, through the appropriate direct participant in DTC and the facilities of DTC, to the trustee, in Form of Notice, to the trustee and to Barclays Bank PLC and will certify to Barclays Bank PLC that the broker or other entity represents the deceased beneficial owner. The broker or other entity will be responsible for disbursing payments received from the trustee, through the facilities of DTC, to the authorized representative of the deceased beneficial owner.

During any time in which the Notes are not represented by a global note and are issued in definitive form:

- all references in this section to participants and DTC, including the DTC's governing rules, regulations and procedures, will be deemed to include the broker or other entity;
- all determinations that the DTC participants are required to make as described in this section will be made by Barclays Bank PLC, in its sole discretion, and in determining whether the applicable decedent is in fact the beneficial owner of the interest in the Notes to be redeemed or is in fact the authorized representative of the decedent, Barclays Bank PLC is duly authorized to request redemption on behalf of the applicable beneficial owner; and
- all redemption requests, to be effective, must:
 - be delivered by the representative to Barclays Bank PLC and to the trustee;
 - be in the form of the attached to this pricing supplement, and must be completed in accordance with the related instructions;
 - be accompanied by, if applicable, a properly executed assignment or endorsement, in addition to all documents required to accompany a redemption request. If the record holder of the Note is a nominee of the deceased beneficial owner, the record holder or the nominee attesting to the deceased's ownership of a beneficial interest in the Note must also be delivered.

Barclays Bank PLC retains the right to limit the aggregate principal amount of Notes as to which exercises of the Survivor's Option will be made, and to limit the number of representatives of deceased beneficial owners and from the authorized representative for any individual deceased beneficial owner in any one exercise.

Pricing Supplement BARC 13yr 5.00% with Survivor's Option Black

other questions regarding the eligibility or validity of any exercise of the Survivor's Option generally will be determined by Barclays Bank and binding on all parties.

Forms for the exercise of the Survivor's Option may be obtained from Barclays Bank PLC, 745 Seventh Avenue, New York, NY 10019, At telephone: 212-412-1535.

PS-3

Pricing Supplement BARC 13yr 5.00% with Survivor's Option Black

UNITED STATES FEDERAL INCOME TAX TREATMENT

The following discussion supplements the discussion in the prospectus supplement under the heading “Certain U.S. Federal Income Tax Considerations” to the extent inconsistent therewith. The following discussion (in conjunction with the discussion in the prospectus supplement) summarizes certain federal income tax consequences of the purchase, beneficial ownership, and disposition of the Notes.

We intend to treat the Notes as indebtedness for U.S. federal income tax purposes and any reports to the Internal Revenue Service (the “IRS”) will reflect such treatment, and each holder will agree to treat the Notes as indebtedness for U.S. federal income tax purposes. The discussion that follows summarizes the federal income tax treatment of the Notes.

Interest paid on the Notes will be taxable to a U.S. holder as ordinary interest income at the time it accrues or is received in accordance with applicable law, without accounting for tax purposes. See “U.S. Federal Income Tax Considerations—Payments of Interest” in the prospectus supplement.

3.8% Medicare Tax On “Net Investment Income”

Beginning in 2013, U.S. holders that are individuals, estates, and certain trusts will be subject to an additional 3.8% tax on all or a portion of their net investment income. Net investment income may include the interest payments and any gain realized with respect to the Notes, to the extent of their net investment income that when added to the holder's other income, exceeds \$200,000 for an unmarried individual, \$250,000 for a married taxpayer filing a joint return (or a surviving spouse), or \$125,000 for a trust filing a separate return. U.S. holders should consult their advisors with respect to their consequences with respect to the 3.8% Medicare tax.

CERTAIN EMPLOYEE RETIREMENT INCOME SECURITY ACT CONSIDERATIONS

Your purchase of a Note in an Individual Retirement Account (an “IRA”), will be deemed to be a representation and warranty by you, as a holder of the IRA, that (i) neither the issuer, the placement agent nor any of their respective affiliates has or exercises any discretionary authority or control with respect to the IRA assets used to purchase the Note or renders investment advice (within the meaning of Section 3(21)(A)(ii) of the Employee Retirement Income Security Act (“ERISA”)) with respect to any such IRA assets and (ii) in connection with the purchase of the Note, the IRA will pay no more than “adequate consideration” (within the meaning of Section 408(b)(17) of ERISA) and in connection with any redemption of the Note pursuant to its terms will receive at least adequate consideration. Without foregoing representations and warranties, you have (x) applied sound business principles in determining whether fair market value will be paid for the Note and (y) acted in good faith.

For additional ERISA considerations, see “Employee Retirement Income Security Act” in the prospectus supplement.

SUPPLEMENTAL PLAN OF DISTRIBUTION

We will agree to sell to Barclays Capital Inc. (the “Agent”), and the Agent will agree to purchase from us, the principal amount of the Notes, if any, to be covered by the cover of this pricing supplement. The Agent will commit to take and pay for all of the Notes, if any are taken.

PS-4

Pricing Supplement BARC 13yr 5.00% with Survivor's Option Black



US\$2,118,000
BARCLAYS BANK PLC

5.00% FIXED RATE NOTES DUE APRIL 28, 2023

GLOBAL MEDIUM-TERM NOTES, SERIES A

(TO PROSPECTUS DATED FEBRUARY 10, 2009, AND THE
PROSPECTUS SUPPLEMENT DATED MARCH 1, 2010)

